Arcturus Therapeutics Holdings Inc. Stock
Equities
ARCT
US03969T1097
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.72 USD | +5.36% | +5.12% | -8.91% |
Financials (USD)
Sales 2024 * | 182M | Sales 2025 * | 229M | Capitalization | 773M |
---|---|---|---|---|---|
Net income 2024 * | -81M | Net income 2025 * | -47M | EV / Sales 2024 * | 2.4 x |
Net cash position 2024 * | 336M | Net cash position 2025 * | - | EV / Sales 2025 * | 3.37 x |
P/E ratio 2024 * |
-9.6
x | P/E ratio 2025 * |
-18.6
x | Employees | 180 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.26% |
Latest transcript on Arcturus Therapeutics Holdings Inc.
1 day | +5.36% | ||
1 week | +5.12% | ||
Current month | +12.32% | ||
1 month | -5.62% | ||
3 months | -25.92% | ||
6 months | +62.17% | ||
Current year | -8.91% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 13-02-28 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 18-12-31 |
Chief Operating Officer | 45 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 19-08-31 |
James F. Barlow
BRD | Director/Board Member | 65 | 18-05-26 |
Peter Farrell
CHM | Chairman | 81 | 18-05-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 28.72 | +5.36% | 277,394 |
24-05-10 | 27.26 | +1.75% | 530,924 |
24-05-09 | 26.79 | -1.54% | 548,718 |
24-05-08 | 27.21 | -1.27% | 317,953 |
24-05-07 | 27.56 | +0.88% | 474,271 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.91% | 734M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- ARCT Stock